NewAmsterdam Pharma Earnings Estimate

NAMS Stock   21.10  0.05  0.24%   
The next projected EPS of NewAmsterdam Pharma is estimated to be -0.5375 with future projections ranging from a low of -0.6275 to a high of -0.455. NewAmsterdam Pharma's most recent 12-month trailing earnings per share (EPS TTM) is at -2.21. Please be aware that the consensus of earnings estimates for NewAmsterdam Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
NewAmsterdam Pharma is projected to generate -0.5375 in earnings per share on the 31st of December 2024. NewAmsterdam Pharma earnings estimates show analyst consensus about projected NewAmsterdam Pharma EPS (Earning Per Share). It derives the highest and the lowest estimates based on NewAmsterdam Pharma's historical volatility. Many public companies, such as NewAmsterdam Pharma, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing NewAmsterdam Pharma's earnings estimates, investors can diagnose different trends across NewAmsterdam Pharma's analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to drop to about 13.9 M in 2025. Pretax Profit Margin is likely to gain to -13.72 in 2025
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Pharma Earnings Estimation Breakdown

The calculation of NewAmsterdam Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of NewAmsterdam Pharma is estimated to be -0.5375 with the future projection ranging from a low of -0.6275 to a high of -0.455. Please be aware that this consensus of annual earnings estimates for NewAmsterdam Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.18
-0.63
Lowest
Expected EPS
-0.5375
-0.46
Highest

NewAmsterdam Pharma Earnings Projection Consensus

Suppose the current estimates of NewAmsterdam Pharma's value are higher than the current market price of the NewAmsterdam Pharma stock. In this case, investors may conclude that NewAmsterdam Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and NewAmsterdam Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
1010.19%
-0.18
-0.5375
-2.21

NewAmsterdam Pharma Earnings History

Earnings estimate consensus by NewAmsterdam Pharma analysts from Wall Street is used by the market to judge NewAmsterdam Pharma's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only NewAmsterdam Pharma's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

NewAmsterdam Pharma Quarterly Gross Profit

29.11 Million

Retained Earnings is likely to gain to about (271 M) in 2025. Earnings Yield is likely to drop to -0.23 in 2025 Common Stock Shares Outstanding is likely to gain to about 99.2 M in 2025, whereas Net Loss is likely to drop (27 M) in 2025.
Hype
Prediction
LowEstimatedHigh
14.7821.0627.34
Details
Intrinsic
Valuation
LowRealHigh
18.0824.3630.64
Details
Naive
Forecast
LowNextHigh
16.6822.9629.23
Details
10 Analysts
Consensus
LowTargetHigh
33.6737.0041.07
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of NewAmsterdam assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards NewAmsterdam Pharma. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving NewAmsterdam Pharma's stock price in the short term.

NewAmsterdam Pharma Earnings per Share Projection vs Actual

Actual Earning per Share of NewAmsterdam Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering NewAmsterdam Pharma predict the company's earnings will be in the future. The higher the earnings per share of NewAmsterdam Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

NewAmsterdam Pharma Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as NewAmsterdam Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of NewAmsterdam Pharma should always be considered in relation to other companies to make a more educated investment decision.

NewAmsterdam Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact NewAmsterdam Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-06
2024-09-30-0.5-0.180.3264 
2024-08-07
2024-06-30-0.58-0.410.1729 
2024-05-08
2024-03-31-0.53-1.06-0.53100 
2024-02-28
2023-12-31-0.55-0.540.01
2023-11-13
2023-09-30-0.8731-0.56420.308935 
2023-08-07
2023-06-30-0.42-1.01-0.59140 
2023-05-08
2023-03-31-0.4237-0.4351-0.0114
2023-03-31
2022-12-31-0.49-1.8-1.31267 
2022-10-18
2022-09-30-1.14-0.26930.870776 

About NewAmsterdam Pharma Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of NewAmsterdam Pharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current NewAmsterdam Pharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as NewAmsterdam Pharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-285.3 M-271 M
Earnings Yield(0.22)(0.23)
Price Earnings Ratio(4.67)(4.90)
Price Earnings To Growth Ratio(0.06)(0.06)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.